TABLE 3.

Adherence Comparison of Index Medication Among Patients with High and Very High Stroke Risk

3 Months
	Rivaroxaban	Dabigatran	Apixaban	P Value
CHA2DS2-VASc = 2 or 3
PDC
Mean (SD)	0.84 (0.25)	0.79 (0.28)	0.83 (0.26)	< 0.001
≥ 0.80, n (%)	2,796 (74.3)	663 (64.8)	760 (73.3)	< 0.001
0.50-0.79, n (%)	394 (10.5)	140 (13.7)	139 (13.4)
< 0.50, n (%)	574 (15.3)	220 (21.5)	138 (13.3)
CHA2DS2-VASc ≥ 4
PDC
Mean (SD)	0.87 (0.24)	0.78 (0.30)	0.85 (0.24)	< 0.001
≥ 0.80, n (%)	2,998 (76.3)	609 (64.0)	1,019 (74.9)	< 0.001
0.50-0.79, n (%)	421 (10.7)	131 (13.8)	173 (12.7)
< 0.50, n (%)	510 (13.0)	212 (22.3)	168 (12.4)
6 Months
CHA2DS2-VASc = 2 or 3
PDC
Mean (SD)	0.75 (0.31)	0.68 (0.33)	0.74 (0.30)	< 0.001
≥ 0.80, n (%)	2,196 (64.1)	511 (52.5)	546 (62.5)	< 0.001
0.50-0.79, n (%)	541 (15.8)	188 (19.3)	163 (18.7)
< 0.50, n (%)	687 (20.1)	274 (28.2)	165 (18.9)
CHA2DS2-VASc ≥ 4
PDC
Mean (SD)	0.79 (0.29)	0.68 (0.34)	0.78 (0.28)	< 0.001
≥ 0.80, n (%)	2,301 (66.4)	474 (53.6)	726 (65.5)	< 0.001
0.50-0.79, n (%)	594 (17.1)	159 (18.0)	216 (19.5)
< 0.50, n (%)	573 (16.5)	252 (28.5)	166 (15.0)
9 Months
CHA2DS2-VASc = 2 or 3
PDC
Mean (SD)	0.69 (0.34)	0.61 (0.35)	0.68 (0.33)	< 0.001
≥0.80, n (%)	1,591 (52.5)	382 (41.9)	340 (48.9)	< 0.001
0.50-0.79, n (%)	501 (16.5)	167 (18.3)	144 (20.7)
< 0.50, n (%)	937 (30.9)	362 (39.7)	211 (30.4)
CHA2DS2-VASc ≥ 4
PDC
Mean (SD)	0.73 (0.32)	0.62 (0.35)	0.74 (0.30)	< 0.001
≥ 0.80, n (%)	1,695 (56.8)	363 (44.4)	492 (58.5)	< 0.001
0.50-0.79, n (%)	539 (18.1)	144 (17.6)	149 (17.7)
< 0.50, n (%)	751 (25.2)	310 (37.9)	200 (23.8)

Note: PDC = sum of days supply from initiation of therapy during the time period divided by time period length (90, 180, or 270 days). Prescription fills were corrected for early refills and credited to the numerator.

PDC = proportion of days covered; SD = standard deviation.